Connect Sign In
Drug Panel, Screen With Reflex to Quantitation, Urine
Ordering Recommendation
Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out drug exposure. This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
New York DOH Approval Status
Specimen Required
Random urine.
Transfer 8 mL urine with no additives or preservatives in ARUP standard transport tubes. (Min: 4 mL)
Refrigerated.
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month
Methodology
Qualitative Enzyme Multiplied Immunoassay Technique (EMIT) / Quantitative Gas Chromatography-Flame Ionization Detection / Quantitative Gas Chromatography-Mass Spectrometry (GC-MS) / Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
Reference Interval
Interpretive Data
Flagging indicates a positive result; not that the result is abnormal.
Presumptive negative results for drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class.
For medical purposes only; not valid for forensic use.
| Drugs covered and range of cutoff concentrations | Screen |
|---|---|
| Amphetamines | Methodology: Immunoassay Positive Cutoff: 300 ng/ml |
| Barbiturates | Methodology: Immunoassay Positive Cutoff: 200 ng/ml |
| Benzodiazepines | Methodology: Immunoassay Positive Cutoff: 200 ng/ml |
| Cocaine | Methodology: Immunoassay Positive Cutoff: 150 ng/ml |
| Ethyl Glucuronide | Methodology: Immunoassay Positive Cutoff: 500 ng/ml |
| Fentanyl | Methodology: Immunoassay Positive Cutoff: 1 ng/ml |
| Opiates | Methodology: Immunoassay Positive Cutoff: 300 ng/ml |
| Oxycodone | Methodology: Immunoassay Positive Cutoff: 100 ng/ml |
| Methadone Metabolite (EDDP) | Methodology: Immunoassay Positive Cutoff: 100 ng/ml |
| Phencyclidine | Methodology: Immunoassay Positive Cutoff: 25 ng/ml |
| THC (Cannabinoids) | Methodology: Immunoassay Positive Cutoff: 50 ng/ml |
FDA
Note
If the specimen screens positive, then confirmation/quantitation by GC/MS, GC/FID, and/or LC-MS/MS will be added to confirm result. Additional charges apply.
To order testing for individual opioids, refer to Fentanyl and Metabolite, Urine, Quantitative (ARUP test code 0092570), Buprenorphine and Metabolites, Urine, Quantitative (ARUP test code 2010092), Meperidine and Metabolite Quantitative, Urine (ARUP test code 3000248), Tramadol and Metabolite, Urine, Quantitative (ARUP test code 2002736). For the comprehensive panel, refer to Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (ARUP test code 2007479).
Hotline History
Hotline History
CPT Codes
80307; if reflexed, add 80321; 80325; 80345; 80346; 80349; 80353; 80354; 80358; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0090386 | Creatinine, Urine | 2161-8 |
| 0092191 | Amphetamines Screen, Urine | 19261-7 |
| 0092192 | Cocaine Screen, Urine | 19359-9 |
| 0092194 | Phencyclidine Screen, Urine | 19659-2 |
| 0092195 | THC (Cannabinoids) Screen, Urine | 19292-2 |
| 0092196 | Barbiturates Screen, Urine | 19270-8 |
| 0092197 | Benzodiazepines Screen, Urine | 14316-4 |
| 2005094 | Opiates Screen, Urine | 19295-5 |
| 2005102 | Oxycodone/Oxymorphone Screen, Urine | 58430-0 |
| 2007913 | Ethyl Glucuronide Screen, Urine | 58375-7 |
| 2012212 | Screen, Urine Interpretation | 54247-2 |
| 2012285 | Fentanyl Screen, Urine | 11235-9 |
| 3020809 | Methadone Metabolite Screen, Urine |
Aliases
- Alcohol, Urine
- Amphetamines, Urine
- Barbiturates, Urine;
- Benzodiazepines, Urine
- Cocaine, Urine
- Creatinine, Urine
- Marijuana, Urine
- Opiates, Urine
- Pain Management
- Phencyclidine, Urine
